Adenocarcinoma of Lung

A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.

Also Known As:

Networked: 14648 relevant articles (694 outcomes, 2547 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Neoplasm Metastasis (Metastasis)
3.	Lung Neoplasms (Lung Cancer)
4.	Squamous Cell Carcinoma (Epidermoid Carcinoma)
5.	Brain Neoplasms (Brain Tumor)

Experts

1.	Yang, Pan-Chyr: 66 articles (01/2021 - 11/2002)
2.	Zhang, Li: 62 articles (06/2022 - 04/2007)
3.	Kris, Mark G: 59 articles (01/2021 - 01/2005)
4.	Wang, Rui: 58 articles (05/2022 - 04/2007)
5.	Zhang, Wei: 57 articles (09/2022 - 08/2004)
6.	Ladanyi, Marc: 56 articles (01/2021 - 01/2005)
7.	Wistuba, Ignacio I: 54 articles (01/2022 - 03/2005)
8.	Wang, Wei: 53 articles (10/2022 - 11/2008)
9.	Li, Wei: 52 articles (06/2022 - 02/2007)
10.	Wang, Yan: 50 articles (06/2022 - 06/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Adenocarcinoma of Lung:

1.	ErbB Receptors (EGF Receptor)IBA 07/09/2015 - "Inhibitors of the Epidermal Growth Factor Receptor (EGFR) May Provide Effective Treatment for Lung Adenocarcinoma." 11/01/2014 - "The therapeutic efficacy was compared among patients with advanced (stages IIIB and IV) lung adenocarcinoma with epidermal growth factor receptor (EGFR)-sensitive mutation. " 08/20/2017 - "There were 85 patients who were diagnosed as advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) 19 or 21 exon mutation in thoracic surgery of Xuanwu Hospital from February 2013 to November 2014, all of who were received EGFR-TKI as first-line treatment in the study. " 10/18/2023 - "The purpose of this study is to identify the clinical, genomic, and transcriptomic features of patients with lung adenocarcinoma (LUAD) harboring uncommon epidermal growth factor receptor (EGFR) mutations (UCM) compared with common EGFR mutations (CM). " 10/13/2023 - "This study investigated the outcome of the impact of epidermal growth factor receptor (EGFR)-TKI in patients with advanced lung adenocarcinoma treated with various therapeutic strategies. "
2.	Tyrosine Kinase InhibitorsIBA 07/01/2023 - "ALK-EML4 fusion-positive lung adenocarcinomas (LUADs) are effectively treated with ALK tyrosine kinase inhibitors, but most patients eventually develop resistance to these drugs owing to ALK-dependent or independent mechanisms. " 05/01/2022 - "Tyrosine kinase inhibitor (TKI) treatment has significantly improved the prognosis of oncogenic-driven lung adenocarcinoma (LUAD). " 01/01/2021 - "Our experience suggests that the use of tyrosine kinase inhibitors (TKIs) as front-line treatment is a more reasonable and safe option for EGFR-mutated lung adenocarcinoma, with ICIs considered as a possible further treatment in sequential approaches." 01/01/2021 - "The development of a new generation of tyrosine kinase inhibitors (TKIs) has improved the treatment response in lung adenocarcinomas. " 03/01/2018 - "EGFR tyrosine kinase inhibitor (EGFR TKI) is approved as first-line treatment for advanced-stage EGFR mutant lung adenocarcinoma (LADC). "
3.	Gefitinib (Iressa)FDA Link 11/01/2021 - "We present an extremely rare case of lung adenocarcinoma that was completely cured by gefitinib administration. " 02/01/2011 - "[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib]." 01/01/2007 - "[A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib]." 01/01/2020 - "It was revealed that TP combined with gefitinib synergistically inhibited the migration and invasion of lung adenocarcinoma cell line A549; the combination treatment had a significantly better outcome than that of TP and gefitinib alone. " 09/01/2015 - "Gefitinib treatment significantly improved the survival of patients with advanced lung adenocarcinoma in China."
4.	Pemetrexed (MTA)FDA Link 01/01/2015 - "We investigated the impact of the genetic polymorphisms on the therapeutic efficacy of pemetrexed in lung adenocarcinoma patients. " 01/01/2023 - "Pemetrexed-based immunochemotherapy represents an established standard of care as first line treatment for non-oncogenic driven metastatic non-small cell lung adenocarcinoma (NSCLC/ADC). " 01/01/2022 - "Furthermore, in a lung adenocarcinoma retrospective cohort (N = 72) from the published BATTLE2 clinical trial (NCT01248247), MTAPdef associates with an improved response rate to pemetrexed. " 09/01/2017 - "Survival of patients with advanced stage IIIB/IV lung adenocarcinoma has improved over the past decade, and is potentially associated with the use of EGFR TKI and pemetrexed." 04/01/2016 - "Our data suggest miR-25, miR-145, and miR-210 as predictors for the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who were negative for EGFR mutations or ALK translocations."
5.	AfatinibIBA 01/01/2019 - "Moreover, use of afatinib may provide significantly improved PFS in patients with advanced lung adenocarcinoma with one of these two EGFR mutations." 01/01/2019 - "First-line afatinib treatment is beneficial for advanced lung adenocarcinoma patients with sensitive EGFR mutations. " 01/01/2020 - "Afatinib is an effective first-line treatment for patients with lung adenocarcinoma harboring complex EGFR mutations, especially those with uncommon mutation patterns." 01/01/2019 - "Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations." 01/01/2018 - "Afatinib exhibits therapeutic efficacy for lung adenocarcinoma patients harboring HER2 exon 20 insertions. "
6.	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/01/2017 - "Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report." 10/01/2018 - "Seventy-two EGFR-positive lung adenocarcinoma patients of Hispanic origin, who underwent first-line treatment with erlotinib, were evaluated for EGFRamp by fluorescence in situ hybridization (FISH). " 05/25/2018 - "EGFR mutation-positive, locally advanced or metastatic lung adenocarcinoma patients received as first line treatment erlotinib at 150 mg/day. " 05/25/2018 - "Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial." 01/01/2016 - "In addition, in vitro cellular uptake, luminescent cell viability assay and colony formation assay were performed to evaluate efficacy of erlotinib loaded CSLPHNPs in A549 cells, a human lung adenocarcinoma cell line. "
7.	Biomarkers (Surrogate Marker)IBA 01/01/2022 - "Because of the high incidence and poor prognoses of lung adenocarcinoma (LUAD), it is essential to identify cost-effective treatment options and accurate and reliable prognostic biomarkers. " 07/19/2012 - "The level of MCP-1 in PE appears to be a reliable surrogate marker for evaluating the therapeutic efficacy in the control of MPE and predicting survival in lung adenocarcinoma patients with MPE." 01/01/2021 - "We believe these key genes may be potential biomarkers for improved prognosis and treatment of lung adenocarcinoma." 01/01/2019 - "The proteomic profiles identified here contribute to an improved understanding of HSP90 inhibition and open possibilities for the detection of potential response biomarkers which will be essential to maximize treatment efficacy in lung adenocarcinoma." 07/01/2021 - "Identification of functional genes or biomarkers may be helpful for developing new treatment strategies in lung adenocarcinoma (LUAD). "
8.	osimertinibIBA 01/01/2021 - "Here, we report the case of a Chinese patient with lung adenocarcinoma (LADC) harboring a T790I mutation who achieved significant benefits from osimertinib treatment." 08/01/2019 - "These findings suggest that osimertinib is beneficial for lung adenocarcinoma patients with squamous cell transformation harboring the T790M mutation." 06/01/2021 - "We found that the first-line treatment with osimertinib was safe and resulted in a long-term response in elderly patients with de novo EGFR T790M-mutated lung adenocarcinoma." 04/12/2023 - "Here, we investigated the efficacy of two novel CDK12/13 inhibitors, AU-15506 and AU-16770, in osimertinib-resistant EGFR mutant lung adenocarcinoma cells in culture and xenograft models in vivo. " 10/01/2022 - "Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic EGFR delL747_S752 and germline BIM deletion polymorphism: a case report and literature review."
9.	Immune Checkpoint InhibitorsIBA 01/01/2020 - "Immune checkpoint inhibitors are effective in some cases of lung adenocarcinoma (LUAD). " 09/28/2023 - "TTF-1-negative status is a poor prognostic factor, and TTF-1-negative lung adenocarcinoma is associated with poor efficacy of immune checkpoint inhibitor (ICI) monotherapy. " 07/01/2023 - "Immune checkpoint inhibitors (ICIs) have been shown to improve clinical outcomes in patients with lung adenocarcinoma (LUAD). " 01/01/2022 - "Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma." 01/01/2022 - "Immune checkpoint inhibitors (ICIs) emerge as the first-line treatment of lung adenocarcinoma (LUAD); selection of subpopulations acquiring clinical benefit is required. "
10.	Cisplatin (Platino)FDA LinkGeneric 02/01/2015 - "It is increasingly used as first-line treatment in combination with cisplatin in lung adenocarcinoma, and as second-line treatment or maintenance monotherapy in patients mainly controlled by the first-line to progression or poor tolerance. " 01/01/2023 - "This study aimed to look into the roles and mechanisms of HNF4G in cisplatin resistance of lung adenocarcinoma. " 12/06/2022 - "Herein, we have proposed a microchip-based system to study the drug resistance of a wild-type human lung adenocarcinoma cell line (A549/WT) induced by EVs derived from A549/DDP cells that are resistant to cisplatin (DDP) inherently. " 11/17/2022 - "The results of this study can provide a new direction and target for clinical research on the reversal of cisplatin resistance in lung adenocarcinoma." 11/17/2022 - "In this study, the potentially related differential expression gene for cisplatin resistance in lung adenocarcinoma was screened in the GEO database. "

Therapies and Procedures

1.	Therapeutics 11/17/2023 - "Covalent inhibitors targeting KRAS-G12C mutation have improved treatment for some patients, but most KRAS-mutant lung adenocarcinoma (KRAS-MT LUAD) cases lack targeted therapies. " 01/01/2023 - "BC was highly expressed in 428 patients with lung adenocarcinoma (LUAD) and high BC expression correlated with reduced efficacy of EGFR-TKI therapy. " 01/01/2019 - "LCT combined with TKIs therapy was a feasible method that significantly improved PFS and OS among oligometastatic lung adenocarcinoma patients with EGFR mutations, and it thus might be considered as an important medical treatment during clinical management." 10/01/2013 - "In an era of targeted therapy for lung adenocarcinomas, EBUS-TBNA is effective in clinical practice for complete diagnosis, staging, and treatment planning in these patients." 10/01/2016 - "In addition, a MET splicing variant of exon 14, has been reported in 2-4% of lung adenocarcinoma and recent studies suggests that targeted therapies inhibiting MET signaling would be beneficial for patients with this alteration. "
2.	Drug Therapy (Chemotherapy) 01/01/2021 - "Postoperative chemotherapy also significantly improved the disease-free survival in patients with either a micropapillary or a solid pattern in stage IB lung adenocarcinoma (postoperative chemotherapy vs. non-postoperative chemotherapy, hazard ratio = 0.51, 95% confidence interval, 0.40-0.64; P < 0.001). " 01/01/2020 - "Because CLDN1 enhances the efficacy of chemotherapy, CLDN1 is not only a prognostic marker but a predictive marker for lung adenocarcinoma patients who are good candidates for chemotherapy. " 01/01/2020 - "Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study." 02/01/2023 - "Radiomics is expected to provide more valuable information for evaluating the chemotherapy efficacy of lung adenocarcinoma." 07/06/2017 - "Metastatic ALK-rearranged lung adenocarcinoma patients treated with ALK inhibitors demonstrate higher response rates, improved progression-free survival, and reduced toxicity relative to those treated with conventional chemotherapy regimens. "
3.	Immunotherapy 04/17/2023 - "The limited efficacy of currently approved immunotherapies in EGFR-mutant lung adenocarcinoma (LUAD) underscores the need to better understand mechanisms governing local immunosuppression. " 01/01/2023 - "Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report." 01/01/2021 - "Therefore, miR-1 could be a clinically useful marker to predict therapeutic efficacy of immunotherapy in lung adenocarcinoma patients with EGFR-TKI resistance." 04/01/2004 - "We conclude that active specific immunotherapy using DCs pulsed with CEA652 is a safe and feasible treatment that is clinically effective in some patients with metastatic gastrointestinal or lung adenocarcinomas. " 01/01/2023 - "Immunotherapy for lung adenocarcinoma (LUAD) is considered to be a promising treatment option, but only a minority of patients benefit from it. "
4.	Radiotherapy 01/01/2022 - "Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study." 11/30/2021 - "This retrospective study aimed to evaluate the difference in efficacy of these radiotherapy modes in patients with EGFR-mutant lung adenocarcinoma with BMs. " 08/29/2023 - "This study aimed to determine the role of local ablative radiotherapy (LART) in oligometastatic/oligoprogressive lung adenocarcinoma. " 01/01/2023 - "This study showed that these inflammatory indices might have an important prognostic potential for advanced lung adenocarcinoma patients with EGFR mutations, receiving thoracic radiotherapy and might provide a basis for the individualized treatment of these patients." 12/01/2022 - "Overall, our findings reveal that GCNT3 is an important factor affecting the radiotherapy sensitivity of lung adenocarcinoma, and GCNT3 inhibition deserves further study as a radiotherapy sensitising strategy."
5.	Adjuvant Chemotherapy 07/01/2015 - "Adjuvant chemotherapy for lung adenocarcinoma patients with positive PLC findings significantly improved recurrence-free survival." 01/01/2017 - "This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients." 07/01/2015 - "Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings." 10/27/2023 - "Although histological subtype in lung adenocarcinoma has been reported as a poor prognostic factor in several studies, its utility has not yet been revealed as an adaptation criterion of postoperative adjuvant chemotherapy. " 01/01/2022 - "This study aimed to develop and validate a radiomic signature (RS) for prediction of OS and adjuvant chemotherapy candidates in stage I lung adenocarcinoma. "